As our Firm continues to hear from individuals who allegedly sustained acetaminophen-induced liver damage caused by Tylenol products, we are obviously pleased to see claims continuing to be filed in the federal Pennsylvania litigation."
New York, NY (PRWEB) May 26, 2014
A number of additional Tylenol lawsuits (http://www.tylenollawsuitcenter.com/) alleging liver damage have been filed in a federal litigation currently underway in the U.S. District Court, District of Eastern Pennsylvania over the past month, Bernstein Liebhard LLP reports.
According to court documents updated on May 15th, a total of 142 cases have now been filed in the federal multidistrict litigation against Johnson & Johnson and its subsidiary, McNeil Consumer Healthcare. Plaintiffs in these Tylenol lawsuits claim to have experienced liver damage caused by its active ingredient, acetaminophen; a risk these companies allegedly failed to warn about in their marketing of the pain reliever. (In Re: Tylenol (Acetaminophen) Marketing, Sales Practices and Products Liability Litigation, MDL No. 2436)
“As our Firm continues to hear from individuals who allegedly sustained acetaminophen-induced liver damage caused by Tylenol products, we are obviously pleased to see claims continuing to be filed in the federal Pennsylvania litigation,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently evaluating potential Tylenol lawsuits on behalf of individuals who were allegedly harmed by the medication.
Tylenol Lawsuits and Liver Damage
As more Tylenol lawsuits are filed in the Eastern District of Pennsylvania, the U.S. Food and Drug Administration (FDA) continues to warn the public about liver side effects that may be associated with acetaminophen. The FDA published its most recent notice on April 28th that advised doctors against prescribing medications that contain more than 325 milligrams of the ingredient, given its alleged potential to cause liver damage. Prior to this announcement, the Los Angeles Times reported last month that the FDA posted a similar health alert in January 2014, at which time the general public was informed that acetaminophen is the second-leading cause of liver failure requiring the need for a transplant in the U.S.*
Bloomberg.com reported in August 2013 that over-the-counter Extra Strength Tylenol exceeds the FDA’s recommended amount of acetaminophen for prescription medications, with each caplet containing 500 mg. Also that month, McNeil Consumer Healthcare alerted the public of its plans to adjust Tylenol’s labeling to include more information about its alleged link to liver damage. **
Alleged victims of acetaminophen-induced liver damage caused by a Tylenol-brand over-the-counter product may be eligible to seek compensation for medical bills, lost wages, pain and suffering, and more. Learn more about Tylenol’s alleged association with liver damage by visiting Bernstein Liebhard LLP’s website. To arrange for a free legal review, please call 800-511-5092.
*latimes.com/science/sciencenow/la-sci-sn-extra-strength-acetaminophen-fda-20140428,0,6108401.story, LA Times, April 28, 2014
**bloomberg.com/news/2013-08-29/j-j-adds-warning-to-tylenol-caps-on-acetaminophen-risk.html, Bloomberg.com, August 29, 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.tylenollawsuitcenter.com/
https://plus.google.com/115936073311125306742?rel=author